Abstract
Fundamental and clinical studies of cefotetan (CTT, YM 09330), a new cephamycin, were performed and following results were obtained.
1) Antibacterial activity
The in vitro antimicrobial activity of cefotetan was compared with cefazolin and cefmetazole against 38 strains of E. coil and Klebsiella. Against both organisms, cefotetan had more dominant activity than others with the peak MIC level of 0.2μg/ml.
2) Absorption and excretion
Serum levels of cefotetan decreased very slowly after single intravenous injection. The excretion of cefotetan in bile was examined on 3 patients with biliary tract disease. Cefotetan showed high tendency in biliary recovery.
3) Clinical results
Cefotetan was administered to 31 cases with surgical infections and clinical results were excellent in 6 cases, good in 18, fair in 5 and poor in 2. As side effects, drug eruption was found in one case and slight elevation serum transaminases in one case.
